Nabriva Therapeutics Plc Quick Ratio (NBRV) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nabriva Therapeutics Plc  (NASDAQ: NBRV)

Nabriva Therapeutics Plc's Quick Ratio

NBRV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Nabriva Therapeutics Plc's Cash & cash equivalent grew by 21.36 % in the Q2 2023 sequentially, while Current Liabilities decreased, this led to improvement in Nabriva Therapeutics Plc's Quick Ratio to 0.08, Quick Ratio remained below Nabriva Therapeutics Plc average.

Within Major Pharmaceutical Preparations industry 564 other companies have achieved higher Quick Ratio than Nabriva Therapeutics Plc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 4068 to 4625.

Explain Quick Ratio?
How much Cash & cash equivalents NBRV´s has?
What are NBRV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBRV Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 35.54 % 72.08 % 25.67 % 11.83 % 3.67 %
Y / Y Cash & cash equivalent Change -89.11 % -94.68 % -73.96 % -71.84 % -67.23 %
Quick Ratio MRQ 0.08 0.06 0.45 0.68 1.04
NBRV's Total Ranking # 4625 # 4068 # 2960 # 2383 # 2000
Seq. Current Liabilities Change -6.41 % 1.42 % 27.56 % 11.94 % 18.82 %
Seq. Cash & cash equivalent Change 21.36 % -85.52 % -15.25 % -26.91 % -40.68 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 565
Healthcare Sector # 1102
Overall Market # 4625


Quick Ratio Statistics
High Average Low
7.87 3.74 0.06
(Mar 31 2018)   (Mar 31 2023)




Financial Statements
Nabriva Therapeutics Plc's Current Liabilities $ 26 Millions Visit NBRV's Balance sheet
Nabriva Therapeutics Plc's Cash & cash equivalent $ 2 Millions Visit NBRV's Balance sheet
Source of NBRV's Sales Visit NBRV's Sales by Geography


Cumulative Nabriva Therapeutics Plc's Quick Ratio

NBRV's Quick Ratio for the trailling 12 Months

NBRV Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 34.49 % 26.68 % 9.46 % 8.03 % 18.43 %
Y / Y Cash & cash equivalent TTM Growth -79.78 % -74.87 % -62.49 % -44.52 % -22.65 %
Quick Ratio TTM 0.3 0.51 0.95 1.47 2
Total Ranking TTM # 4587 # 4181 # 4106 # 1289 # 3985
Seq. Current Liabilities TTM Growth 7.11 % 13.82 % 7.12 % 2.98 % 0.9 %
Seq. Cash & cash equivalent TTM Growth -36.52 % -39.54 % -30.36 % -24.34 % -21.13 %

Quick ratio ranking by company, industry and sector >> Back to NBRV Financial Strength Comparisons >> Go to Compare NBRV Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2023 to $26.20 millions, cumulative Quick Ratio decreased to 0.3 below the Nabriva Therapeutics Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 576 other companies have achieved higher Quick Ratio than Nabriva Therapeutics Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 4181 to 4587.

Explain Quick Ratio?
How much Cash & cash equivalents NBRV´s has?
What are NBRV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 577
Healthcare Sector # 1159
Within the Market # 4587


trailing twelve months Quick Ratio Statistics
High Average Low
6.98 3.88 0.3
(Jun 30 2018)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Grifols Sa  0.23 $ 593.126  Millions$ 2,593.476  Millions
Kamada Ltd   0.21 $ 21.788  Millions$ 102.639  Millions
Avenue Therapeutics Inc   0.20 $ 1.571  Millions$ 7.812  Millions
Palatin Technologies Inc   0.20 $ 2.993  Millions$ 15.132  Millions
Ibio inc   0.20 $ 4.351  Millions$ 22.109  Millions
Intelgenx Technologies Corp   0.19 $ 2.225  Millions$ 11.597  Millions
Molecular Templates Inc   0.18 $ 4.952  Millions$ 26.937  Millions
Agile Therapeutics Inc  0.18 $ 2.785  Millions$ 15.309  Millions
Tiziana Life Sciences Ltd  0.18 $ 1.183  Millions$ 6.539  Millions
Eagle Pharmaceuticals inc   0.18 $ 15.354  Millions$ 86.630  Millions
Biofrontera Inc   0.18 $ 4.453  Millions$ 25.352  Millions
Scienture Holdings Inc   0.17 $ 0.746  Millions$ 4.263  Millions
Lunai Bioworks Inc   0.17 $ 1.874  Millions$ 10.830  Millions
Eli Lilly And Company  0.15 $ 2,829.100  Millions$ 18,915.000  Millions
Keenova Therapeutics Plc  0.15 $ 480.600  Millions$ 3,255.300  Millions
Amneal Pharmaceuticals Inc   0.15 $ 114.582  Millions$ 777.350  Millions
NIKA PHARMACEUTICALS, INC  0.15 $ 0.011  Millions$ 0.076  Millions
Evelo Biosciences Inc   0.14 $ 7.622  Millions$ 52.851  Millions
Promis Neurosciences inc   0.14 $ 1.254  Millions$ 8.739  Millions
Astrazeneca Plc  0.14 $ 6,504.000  Millions$ 45,834.000  Millions
Abvc Biopharma Inc   0.14 $ 0.819  Millions$ 5.773  Millions
Organon and Co   0.14 $ 326.000  Millions$ 2,387.000  Millions
Comera Life Sciences Holdings Inc   0.13 $ 0.520  Millions$ 3.954  Millions
Emergent Biosolutions Inc   0.13 $ 88.600  Millions$ 693.200  Millions
Impel Pharmaceuticals Inc   0.13 $ 15.162  Millions$ 121.221  Millions
Avid Bioservices Inc   0.12 $ 24.898  Millions$ 205.944  Millions
Journey Medical Corp  0.12 $ 8.230  Millions$ 68.193  Millions
Nexien Biopharma Inc   0.12 $ 0.035  Millions$ 0.295  Millions
REGENEREX PHARMA, INC.  0.12 $ 0.068  Millions$ 0.586  Millions
Allarity Therapeutics Inc   0.11 $ 1.420  Millions$ 12.668  Millions

Date modified: 2026-09-08T15:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.